Quick Facts

• Treats leishmaniasis: visceral, cutaneous, and mucocutaneous forms.

---

What Мегион Treats: Main Uses and Benefits

Мегион (meglumine antimoniate) is an established anti-protozoal medication primarily utilized for the management of leishmaniasis, an infection caused by parasitic protozoa. The drug's therapeutic domain specifically includes visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis.

This medication is a pentavalent antimonial and acts to target the parasitic organisms responsible for the disease. For treatment of the infection, Мегион is administered parenterally (by injection). Dosing and the duration of the treatment regimen are determined by a healthcare professional based on the specific form of leishmaniasis and the patient's body weight.

While not commercially available in the United States, meglumine antimoniate is a traditional main-line therapy in many global regions.

Who can and cannot use Мегион?

Мегион (Meglumine Antimoniate) is a specialized anti-protozoal medicine whose eligibility profile is strictly defined by regulatory criteria based on patient population and pre-existing health status.

Approved and Restricted Use

Use is generally documented for adults and children requiring systemic treatment for leishmaniasis. However, the medicine is often not recommended as a first-line therapy for children under one year of age and for older adults over 50 years, where authoritative guidelines frequently indicate preferred alternatives. Use is conditional for all eligible patients and requires mandatory monitoring of liver and kidney function and ECG monitoring due to the risk of cardiotoxicity. Use is also restricted in immunocompromised patients.

Absolute Contraindications

Regulatory documents state that Мегион is contraindicated and must not be used in several populations: pregnant and breastfeeding women due to documented toxicity risks; patients with a known hypersensitivity to pentavalent antimonials; patients with severe renal, hepatic, or cardiac failure or pre-existing pancreatitis; and individuals with a known risk for QT interval prolongation.

Interactions with other medicines and products

The official interaction profile for Мегион is primarily defined by the risk of pharmacodynamic reinforcement of inherent toxicities, rather than alterations via metabolic enzymes or drug transporters.

Documented Interaction Patterns

The regulatory information emphasizes caution regarding co-administration with two main categories of medicines due to additive toxicity risk.

• QT-prolonging medicines: Concomitant use with other medicinal products known to prolong the QT interval may increase the risk of serious cardiac dysrhythmias. This constitutes a pharmacodynamic interaction of additive cardiotoxicity, as noted in authoritative public health guidance.

• Nephrotoxic medicines: Co-administration with agents known to impair renal function, such as Amphotericin B or certain aminoglycosides, increases the risk of cumulative nephrotoxicity. This additive effect is clinically significant because Мегион is primarily eliminated by the kidneys.

Category	Interaction Focus
Mechanism Basis	Pharmacodynamic Reinforcement
Key Restriction	Additive QT risk; Additive Renal Toxicity

Population-Specific Interaction Notes

The potential for interaction-related toxicity, including reduced clearance and heightened cumulative risk, is explicitly noted in individuals with pre-existing renal impairment. The official profile does not document interactions with food, alcohol, or herbal products, nor does it list specific timing or separation requirements for administration.

Мегион, whose active ingredient is Ceftriaxone, functions by a method that results in the destruction of susceptible bacteria. The mechanism acts exclusively upon structures and processes unique to the bacterial cell.

Targeting Bacterial Cell Wall Construction

The mechanism begins with the covalent inactivation of Penicillin-Binding Proteins (PBPs), which are the essential bacterial enzymes responsible for forming the peptidoglycan cross-links that give the cell wall its structural integrity. By irreversibly binding to and neutralizing these enzymes, Ceftriaxone immediately halts the construction and maintenance of the bacterial protective layer.

Initiating Lysis and Bactericidal Effect

The structural breakdown of the cell wall triggers a destructive cellular event: the activation of the bacteria's own self-digesting enzymes, called autolysins. This combined failure of wall assembly and internal digestion leads quickly to the irreversible rupture (lysis) of the bacterial cell due to osmotic pressure. This bactericidal action results in the physiological clearance of the pathogen population throughout the body.

Understanding Mechanisms of Reduced Efficacy

The primary limitation of this mechanism is when bacteria produce boldsymbolbeta-lactamase enzymes. These bacterial defense molecules chemically break down the drug's active core before it can reach and inhibit the PBP targets. This enzymatic degradation neutralizes the drug's mechanism, leading to the maintenance of bacterial cellular processes and proliferation.

How to Use Мегион

Мегион (Meglumine Antimoniate) is administered exclusively through parenteral routes, meaning it is given by injection. The specific route depends on the condition being addressed, typically involving Intramuscular (IM) injection or Intravenous (IV) infusion for systemic treatment, or Intralesional (IL) injection for localized skin lesions.

---

Dosing and Preparation

Administration is based on the quantity of pentavalent antimony (SbV) contained within the solution. The standard systemic dose for both adults and children is 20 mg of SbV per kilogram of body weight per day (20 mg/kg/day), with a maximum daily limit of 850 mg of SbV.

When the IV route is selected, the required dose must first be diluted in 50 mL of a compatible solution, such as Normal Saline or Dextrose 5% in Water (D5W), and should be infused slowly over a minimum period of 10 minutes. The solution must not be mixed with other medications.

---

Frequency and Duration

The systemic dose is administered once daily (q.d.) on a fixed schedule. The standard course duration for systemic treatment of visceral and mucocutaneous leishmaniasis is typically 20 to 28 consecutive days.

Administration Adjustments

Prescribing information indicates that the dose may require reduction or adjustment in patients who have evidence of renal or hepatic impairment, as the body's elimination of the drug relies on these organs. The weight-based dose calculation is maintained for all age groups.

Research Evidence / Overview of Studies for Мегион

Мегион (meglumine antimoniate) has been studied in clinical trials and observational research primarily in the context of leishmaniasis management. The existing evidence helps describe the patterns observed in patient groups and provides context regarding observed changes under specific study conditions.

---

Evidence for Visceral Leishmaniasis (VL)

The research for Visceral Leishmaniasis (VL) includes Randomized Controlled Trials (RCTs) and cohort studies. These studies were generally conducted during periods of increased symptom activity and research examined how patient symptoms evolved over defined time intervals. The outcomes focused heavily on measuring endpoints related to Final Patient Status, which was typically defined by the absence of systemic symptoms and the absence of the parasite. Follow-up periods tracked patients for short-term assessment and up to six months or one year to monitor for infection recurrence.

Studies report how symptoms evolved in the observed populations, with findings describing patterns related to changes in systemic or functional markers. The variability in reported outcomes across different endemic regions complicates generalized conclusions, as results apply only to the populations studied in specific geographical areas.

---

Evidence for Cutaneous Leishmaniasis (CL)

For Cutaneous Leishmaniasis (CL), research examined various methods of administration, including systemic and intra-lesional routes, and research examined short-term symptom changes related to the skin lesions. The key outcomes measured were endpoints related to Complete Lesion Status, defined by the full re-epithelization of the lesion, and the Time to Resolution of Skin Changes. Findings were mixed across systematic reviews, and certainty remains low for some specific findings due to the high heterogeneity in research quality and the wide variety of parasite species studied.

---

Evidence Gaps and Areas of Uncertainty

Across all indications, scientific reviews suggest that evidence quality varies across studies. Specific limitations include the high variability in outcome measurements observed across different geographic regions and species. Additionally, long-term effects are not well characterized beyond the initial monitoring periods, and comparative evidence is often lacking against alternative therapeutic options.

Key Studies & References

1. ASTMH/IDSA Clinical Practice Guidelines for the Diagnosis and Treatment of Leishmaniasis (includes meglumine antimoniate treatment context)
2. Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis (compares MA and miltefosine outcomes and follow-up periods)
3. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis (ML) (discusses MCL research structure, outcomes, and long-term follow-up)
4. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study (discusses specific patient populations and outcomes in children vs. adults)

Common questions about Мегион (FAQ)

Q: Why is Мегион prescribed by doctors?

A: According to official product information, Мегион is indicated for the treatment of severe systemic bacterial infections (as Ceftriaxone). Studies and official information also indicate the drug has been researched for the management of leishmaniasis.

Q: What is the general purpose of the ingredient listed as the 'active substance' in Мегион?

A: The active ingredient is classified as a third-generation cephalosporin antibiotic. This group of medicines is described for the elimination of susceptible pathogenic bacteria in the body.

Q: Is Мегион used for immediate relief or long-term management?

A: The official prescribing information indicates that Мегион is typically given in a fixed, defined course over a specified period. This use is intended to resolve an acute medical condition rather than for indefinite, long-term management.

Q: Is Мегион designed to cure a condition or just manage symptoms?

A: The drug's mechanism of action is bactericidal, which is described as acting to destroy the pathogenic bacteria. This mechanism supports the clearance of the pathogen population.

Q: What does the research say about the overall effectiveness of Мегион?

A: Research evidence for Мегион outlines the specific clinical outcomes that studies tracked in patient groups. These outcomes typically include achieving endpoints such as Final Patient Status or the Complete Lesion Status under specific study conditions.

Q: Does Мегион make you feel tired or sleepy?

A: Regulatory documents do not specifically list tiredness or sleepiness (somnolence) as defined side effects. However, official information notes that effects on the central nervous system may occur, such as headache, which is listed as a Very Common side effect.

Q: Can Мегион affect my ability to drive or operate machinery?

A: Official warnings indicate that there is a potential for certain side effects to affect a person's concentration or ability to perform skilled tasks. This is a common precaution for medicines that can affect the nervous system.

Q: Does Мегион have a risk of dependency or addiction?

A: The official product documentation does not classify this medicine as a controlled substance. Furthermore, warnings related to abuse, dependency, or addiction are not listed in the major regulatory profiles for Мегион.

Q: Does Мегион interact with common pain relievers like ibuprofen?

A: Official information notes that co-administration with any other medicine known to impair renal (kidney) function should be considered carefully. This is due to the potential for an additive effect that increases the risk of cumulative kidney toxicity.

Q: Why do official documents mention 'contraindications' for Мегион?

A: Contraindications are essential statements listed in official documents to define specific situations. They identify conditions where the known risk of serious harm to the patient outweighs any possible benefit that the drug might provide.

Q: Is it normal to feel a mild stomach upset when first starting Мегион?

A: Official side effect profiling lists anorexia (loss of appetite) as a Frequent adverse reaction. While not specifically a stomach ache, this general gastrointestinal discomfort is one of the more commonly reported effects.

Q: Does Мегион interact with commonly used supplements like vitamins?

A: The official interaction profile focuses primarily on drug-to-drug interactions due to additive toxicity risk. The profile does not document specific interactions with food, alcohol, or commonly used herbal products and vitamin supplements.

Q: What does 'research evidence' mean in the context of Мегион?

A: The term 'research evidence' refers to information gathered from formal clinical research. This includes data from human studies, such as Randomized Controlled Trials (RCTs), that are used to establish the context of the drug's approved uses.

Q: What is meant by a 'serious' side effect of Мегион?

A: Serious adverse reactions are formally listed as those with the potential to cause significant, lasting damage to major organ systems. Examples documented for Мегион include acute renal failure and severe hepatic damage (liver damage).

Q: How quickly does Мегион leave the body after stopping use?

A: The rate at which Мегион leaves the body is a purely scientific fact described in the official pharmacokinetic properties section. This rate is expressed as the drug's half-life.

Q: Are there any reported interactions between Мегион and blood pressure medications?

A: Official warnings indicate that the use of QT-prolonging medicines should be considered carefully. This category includes certain types of cardiac or blood pressure medications that can increase the risk of serious heart rhythm changes.

Q: Is Мегион classified as a narcotic or controlled substance?

A: Official regulatory bodies classify this medicine as a prescription drug requiring professional oversight. It is not listed or categorized as a narcotic or controlled substance by major regulatory agencies.

How to Store and Dispose of Meglumine Antimoniate (Мегион)

Storage and disposal instructions for Meglumine Antimoniate solution are based strictly on official regulatory labeling.

Storage and Stability

Condition	Requirement
Temperature	Store the unopened solution at or below 30 C (some labels specify leq 25 C).
Protection	Keep the product in its original packaging and protect it from unauthorized access.
Stability	The solution is for single use; it must be used immediately after the container is opened, and any unused portion must be discarded.

The medicine must be kept out of the sight and reach of children.

Disposal Requirements

Disposal of unused or expired product must follow controlled-waste procedures. The medicine must not be disposed of via wastewater or household trash and should be managed according to local pharmaceutical take-back schemes and regulatory requirements.